ORR in TN and R/R CLL. Shown are ORR by higher-risk genomic feature in the TN CLL cohort (acalabrutinib-based regimens) (A) and R/R CLL cohort (acalabrutinib monotherapy) (B). CR includes CRi; PR includes nPR. CRi, CR with incomplete blood count recovery; nPR, nodular PR; PD, progressive disease; SD, stable disease.